Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000938
Chunk: 22

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 22
---
(d) of the Exchange Act and Rule 13d-3
promulgated thereunder), would result in the beneficial ownership by the Investor and its affiliates of more than 4.99%
of the then issued and outstanding Ordinary Shares following such purchase or acquisition by the Investor (including Ordinary Shares represented
by Depositary Shares) (the “”), , the Investor may increase the
Beneficial Ownership Limitation up to 9.99% at its sole discretion upon sixty-one (61) days’ prior written notice to the Company,
and , if as of the Investor and its affiliates holds 5.0% or more of the outstanding Ordinary Shares (including
Ordinary Shares represented by Depositary Shares) as of the Execution Date then Beneficial Ownership Limitation shall be 9.99%. Upon the
written or oral request of the Investor, the Company shall promptly (but not later than the next Business Day on which the Depositary
is open for business) confirm orally or in writing to the Investor the number of Ordinary Shares (including Ordinary Shares represented
by Depositary Shares) then outstanding. The Investor and the Company shall each cooperate in good faith in the determinations required
hereby and the application hereof. The Investor’s written certification to the Company of the applicability of the Beneficial Ownership
Limitation, and the resulting effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and
such result absent manifest error.

(g) . Notwithstanding any other terms of this Agreement, in no event shall the aggregate amount of Purchase Shares
submitted in any single or combination of VWAP Purchase Notices and/or Additional VWAP Purchase Notices on a particular related VWAP Purchase
Date and/or Additional VWAP Purchase Date require a payment from the Investor that exceeds $2,500,000, unless such limitation is waived
by the Investor in its sole discretion as to any single or combination of VWAP Purchase Notices and/or Additional VWAP Purchase Notices
on a particular related VWAP Purchase Date and/or Additional VWAP Purchase Date.

(h) . With respect to each Fixed Purchase Notice, VWAP Purchase Notice and/or Additional VWAP Purchase Notice, the Company
shall deliver to the Investor a completed form of purchase notice in materially the form attached hereto as .

| -10- |

3. INVESTOR’S REPRESENTATIONS AND WARRANTIES.

The Investor represents and
warrants to the Company that as of the date hereof and as of the Commencement Date:

(a) . Investor is